结外鼻型NK/T细胞淋巴瘤治疗现状

国际肿瘤学杂志››2015,Vol. 42››Issue (7): 554-556.doi:10.3760/cma.j.issn.1673-422X.2015.07.022

结外鼻型NK/T细胞淋巴瘤治疗现状

陶恒敏，魏玉梅，李宝生

250017 济南大学 betway.com 医学与生命科学学院；山东省肿瘤医院放疗六病区

出版日期:2015-07-08发布日期:2015-05-26
通讯作者:李宝生 E-mail:baoshli1963@163.com
基金资助:

山东省自然科学基金（ZR2014YL034）

Current status for the treatment of extranodal nasal type NK/T cell lymphoma

Tao Hengmin, Wei Yumei, Li Baosheng

School of Medicine and Life Sciences, University of Ji′nanShandong Academy of Medical Sciences; Sixth Department of Radiation Oncology, Shandong Cancer Hospital, Ji′nan 250117, China

Online:2015-07-08Published:2015-05-26
Contact:Li Baosheng E-mail:baoshli1963@163.com

摘要/Abstract

摘要：大部分结外鼻型自然杀伤(NK)/T细胞淋巴瘤(ENKTL)处于Ⅰ、Ⅱ期。由于较高的局部和系统性失败率，单纯放疗无法使早期患者获得高治愈率。同步或序贯放化疗成为早期ENKTL的标准治疗方案。对于Ⅲ、Ⅳ期患者，含左旋门冬酰胺酶（LASP）化疗方案的治疗效果最为显著。晚期及复发难治患者常规化疗缓解后，可以接受造血干细胞移植巩固治疗。

关键词:淋巴瘤,结外NKT细胞,放射疗法,药物疗法,造血干细胞移植

Abstract:The most of extranodal nasal type NK/Tcell lymphoma (ENKTL) are in the Ⅰ/Ⅱ stage. Radiotherapy alone is insufficient to achieve a high cure rate for the early stage patients with ENKTL due to frequent local and systemic relapse. Concomitant/sequential chemotherapy and radiotherapy is the standard treatment for the early stage patients with ENKTL. For the patients with stage Ⅲ/Ⅳ ENKTL, regimens containing Lasparaginase are most effective. For the patients with advanced stage ENKTL or refractory recurrent ENKTL, hematopoietic stem cell transplantation may be considered when the remission is achieved.

Key words:Lymphoma, extranodal NKTcell,Radiotherapy,Drug therapy,Hematopoietic stem cell transplantation

陶恒敏，魏玉梅，李宝生. 结外鼻型NK/T细胞淋巴瘤治疗现状[J]. 国际肿瘤学杂志, 2015, 42(7): 554-556.

Tao Hengmin, Wei Yumei, Li Baosheng. Current status for the treatment of extranodal nasal type NK/T cell lymphoma[J]. Journal of International Oncology, 2015, 42(7): 554-556.

参考文献

［1］ Au WY, Weisenburger DD, Intragumtornchai T, et al. Clinical differences between nasal and extranasal natural killer/Tcell lymphoma: a study of 136 cases from the international peripheral Tcell lymphoma project［J］. Blood, 2009, 113(17): 3931-3937. ［2］ Li YX, Yao B, Jin J, et al. Radiotherapy as primary treatment for stage ⅠE and ⅡE nasal natural killer/Tcell lymphoma［J］. J Clin Oncol, 2006, 24(1): 181-189. ［3］ Jiang L, Li SJ, Jiang YM, et al. The significance of combining radiotherapy with chemotherapy for early stage extranodal natural killer/Tcell lymphoma, nasal type: a systematic review and metaanalysis［J］. Leuk Lymphoma, 2014, 55(5): 1038-1048. ［4］ Li YX, Wang H, Jin J, et al. Radiotherapy alone with curative intent in patients with stage Ⅰ extranodal nasaltype NK/Tcell lymphoma［J］. Int J Radiat Oncol Biol Phys, 2012, 82(5): 1809-1815. ［5］聂大红, 谢方云, 李济时, 等. 早期鼻腔NK/T细胞淋巴瘤治疗方法和预后分析［J］. 中华放射肿瘤学杂志, 2010, 19(4): 315-319. ［6］ Lee J, Cho SG, Chung SM, et al. Retrospective analysis of treatment outcomes for extranodal NK/Tcell lymphoma (ENKL), nasal type, stage ⅠⅡE: single institute experience of combined modality treatment for early localized nasal extranodal NK/Tcell lymphoma (ENKL)［J］. Ann Hematol, 2013, 92(3): 333-343. ［7］ Yamaguchi M, Tobinai K, Oguchi M, et al. Phase Ⅰ/Ⅱ study of concurrent chemoradiotherapy for localized nasal natural killer/Tcell lymphoma: Japan clinical oncology group study JCOG0211［J］. J Clin Oncol, 2009, 27(33): 5594-5600. ［8］ Kim SJ, Kim K, Kim BS, et al. Phase Ⅱ trial of concurrent radiation and weekly cisplatin followed by VIPD chemotherapy in newly diagnosed, stage ⅠE to ⅡE, nasal, extranodal NK/Tcell lymphoma: consortium for improving survival of lymphoma study［J］. J Clin Oncol, 2009, 27(35): 6027-6032. ［9］ Kim SJ, Yang DH, Kim JS, et al. Concurrent chemoradiotherapy followed by Lasparaginasecontaining chemotherapy, VIDL, for localized nasal extranodal NK/T cell lymphoma: CISL0801 phase Ⅱ study［J］. Ann Hematol, 2014, 93(11): 1895-1901. ［10］王志辉, 夏忠军, 李苏, 等. 吉西他滨联合奥沙利铂及左旋门冬酰胺酶对Ⅰ/Ⅱ期结外NK/T细胞淋巴瘤的近期疗效及安全性分析［J］. 广东医学, 2011, 32(2): 240-242. ［11］ Jaccard A, Gachard N, Marin B, et al. Efficacy of Lasparaginase with methotrexate and dexamethasone (AspaMetDex regimen) in patients with refractory or relapsing extranodal NK/Tcell lymphoma, a phase 2 study［J］. 2011, 117(6): 1834-1839. ［12］ Yong W , Zheng W, Zhu J, et al. Lasparaginase in the treatment of refractory and relapsed extranodal NK/Tcell lymphoma, nasal type［J］. Ann Hematol, 2009, 88(7): 647-652. ［13］周颖, 蔡清清, 林旭滨, 等. SMILE方案治疗复发难治NK/T细胞淋巴瘤的初步临床报告［J］. 白血病·淋巴瘤, 2009, 18, (4): 213-215. ［14］ Kwong YL, Kim WS, Lim ST, et al. SMILE for natural killer/Tcell lymphoma: analysis of safety and efficacy from the Asia lymphoma study group［J］. Blood, 2012, 120(15): 2973-2980. ［15］ Ennishi D, Maeda Y, Fujii N, et al. Allogeneic hematopoietic stem cell transplantation for advanced extranodal natural killer/Tcell lymphoma, nasal type［J］. Leuk Lymphoma, 2011, 52(7): 1255-1261. ［16］ Li M, Gao C, Li H, et al. Allogeneic haematopoietic stem cell transplantation as a salvage strategy for relapsed or refractory nasal NK/Tcell lymphoma［J］. Med Oncol, 2011, 28(3): 840-845. ［17］ Kwong YL, Anderson BO, Advani R, et al. Management of Tcell and naturalkillercell neoplasms in Asia: consensus statement from the Asian oncology summit 2009［J］. Lancet Oncol, 2009, 10(11): 1093-1101. ［18］ Suzuki R. Treatment of advanced extranodal NK/T cell lymphoma, nasaltype and aggressive NKcell leukemia［J］. Int J Hematol, 2010, 92(5): 697-701.

[1]	高凡, 王萍, 杜超, 褚衍六.肠道菌群与结直肠癌非手术治疗的相关研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 376-381.
[2]	张洁, 范玲, 李杰, 温华, 苏媛媛, 路宁, 张明鑫.原发性胰腺淋巴瘤1例并文献复习[J]. 国际肿瘤学杂志, 2024, 51(5): 316-320.
[3]	李书月, 马辰莺, 周菊英, 徐晓婷, 秦颂兵.寡转移非小细胞肺癌的放疗进展[J]. 国际肿瘤学杂志, 2024, 51(3): 170-174.
[4]	李济时, 陆钊群, 刘俊茹, 吕建勋, 陈霜, 沈琳, 徐志渊, 吴平安.新辅助放疗联合部分喉切除术治疗喉滑膜肉瘤1例并文献复习[J]. 国际肿瘤学杂志, 2024, 51(2): 123-125.
[5]	金旭东, 陈忠坚, 毛伟敏.MTAP基因在恶性间皮瘤中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(2): 99-104.
[6]	中国医师协会放射肿瘤治疗医师分会, 中华医学会放射肿瘤治疗学分会, 中国抗癌协会肿瘤放射治疗专业委员会.中国食管癌放射治疗指南（2023年版）[J]. 国际肿瘤学杂志, 2024, 51(1): 1-20.
[7]	高新雨, 李振江, 孙洪福, 韩丹, 赵倩, 刘成新, 黄伟.基于MR加速器的MR引导放疗在食管癌患者中的临床应用[J]. 国际肿瘤学杂志, 2024, 51(1): 37-42.
[8]	崔腾璐, 吕璐, 孙鹏飞.放疗联合免疫治疗在头颈部鳞状细胞癌治疗中的应用[J]. 国际肿瘤学杂志, 2023, 50(9): 548-552.
[9]	李晨曦, 赵宏伟.二次肿瘤细胞减灭术治疗初始减瘤手术不满意铂敏感复发性卵巢癌的预后及影响因素分析[J]. 国际肿瘤学杂志, 2023, 50(6): 342-347.
[10]	李青珊, 谢鑫, 张楠, 刘帅.放疗联合系统治疗在乳腺癌中的应用进展[J]. 国际肿瘤学杂志, 2023, 50(6): 362-367.
[11]	许萌, 姜伟, 朱海涛, 曹雄锋.癌相关成纤维细胞在肿瘤放疗抵抗中的研究进展[J]. 国际肿瘤学杂志, 2023, 50(4): 227-230.
[12]	石小琪, 汪红艳.肠道菌群与放射性肠炎的相互作用及研究进展[J]. 国际肿瘤学杂志, 2023, 50(4): 244-247.
[13]	李进芝, 赵彪, 文晓博, 张明, 袁美芳, 孙梦真, 蒲琴, 杨毅.Monaco系统计算网格尺寸对T₄期鼻咽癌的剂量学影响[J]. 国际肿瘤学杂志, 2023, 50(11): 641-649.
[14]	耿睿, 马俊强, 郭强, 牛钊峰.老年乳腺癌患者的综合治疗方式选择倾向及其影响因素[J]. 国际肿瘤学杂志, 2023, 50(11): 650-654.
[15]	王冰, 王爱馥, 刘雯舒, 范娇娇, 田伟成, 王玮莉, 刘博宇.重组人血小板生成素治疗肿瘤放疗所致血小板减少症的疗效及安全性[J]. 国际肿瘤学杂志, 2023, 50(11): 661-667.